Scinai Registers Resale of 7.59M Warrants-Linked ADSs From October Financing
SCNI is trading near its 52-week low of $0.503 (6.2% above the low).
Summary
Scinai filed the resale registration for 7,587,543 ADSs underlying the warrants from its October 2026 private placement and warrant inducement. Resales bring the company no proceeds, and the roughly $6.16 million of potential exercise proceeds is unlikely at current prices given $1.20 and $1.32 strikes.
Key Events · Financing and Capital Events · SCNI
-
Resale Registration Covers 7.59M ADSs
The F-3 registers up to 7,587,543 ADSs for resale by Armistice Capital Master Fund (7,464,626 ADSs) and A.G.P./Alliance Global Partners (122,917 ADSs), all issuable on exercise of Pre-Funded, Series A-1 and Placement Agent Warrants from the October 2026 transactions.
-
Company Gets No Resale Proceeds
Selling shareholders receive all sale proceeds; Scinai only receives exercise prices if warrants are exercised for cash. Full cash exercise would yield about $6.16 million gross, but the filing states the $1.20 and $1.32 strikes may exceed the trading price, making exercise unlikely.
-
Placement Agent Warrant Terms Set
A.G.P. holds 122,917 warrants at $1.32 per ADS, first exercisable April 15, 2027 and expiring April 15, 2032, with a 180-day transfer restriction; A.G.P. also received a cash fee of up to 7.0% of gross proceeds plus up to $75,000 in expenses.
-
Registration Deadline and Penalties
The registration rights agreement required filing within 15 calendar days of the October 13, 2026 closing and effectiveness within 60 days (90 days if SEC review), with liquidated damages of $1,000 per day for certain failures.
Analysis · SCNI · Life Sciences
The warrant overhang from Scinai's October 2026 financing becomes tradable under this F-3: up to 7,587,543 ADSs can be resold by Armistice Capital and placement agent A.G.P. once the registration goes effective. Those resales generate nothing for the company — only the exercise prices if the warrants are exercised for cash, and at $0.53 per ADS against $1.20 and $1.32 strikes that is unlikely near term. The $6.16 million of hypothetical exercise proceeds should not be counted as funding; the filing itself says so. Against a going-concern history and an ADS price back below Nasdaq's $1.00 minimum bid, the practical read is continued pressure on the share price from resale supply rather than new capital.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 31.1% of the 1661 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCNI was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $302.7K. The 52-week trading range was $0.50 to $15.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.